IP Library Granted Patent US 12,362,040
Granted Patent B2
US 12,362,040 · App. 17/768,625 · Granted Jul 15, 2025

Systems and methods for spatial mapping of expression profiling

Inventors: Peter Askovich (Seattle, WA); Gayathri Balasundaram (Sammamish, WA); Joseph M. Beechem (Eugene, OR); Michael McKean (Gig Harbor, WA); Bishop Wilkins (Seattle, WA)
Assignee: Bruker Spatial Biology, Inc.
G16B25/00G06T7/0012G06T9/00G06V10/25G06V20/695G06T2207/20036G06T2207/30024
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,362,040
App. No.
17/768,625
Granted
Jul 15, 2025
Kind
B2
Abstract

Systems, apparatuses and methods for spatially mapping at least one biological expression of a target biological component contained in a tissue sample to an image of the tissue sample are provided. In some embodiments, the system includes a processor and instructions that, when executed by the processor, cause the system to display, in a first display, a scans pane including at least the image of the tissue sample, the image including at least one demarcation corresponding to a region-of-interest (ROI(s)), where the ROI(s) correspond to a portion of the tissue within the tissue image. The instructions are further configured to cause the system to display, in a second display, a visualization pane including a visualization of the biological expression contained in the ROI(s); and to augment the first display by coding the ROI(s) in the tissue image to show the spatial mapping of the biological expression within the ROI(s).

Claims (37)

1. A tissue sample biological expression mapping system configured to spatially map one or more biological expressions of respective target biological components contained in a tissue sample to an image of the tissue sample, the system comprising at least one processor having instructions operational thereon that, when executed, are configured to cause the system to:

display, in a first display, a scans pane which includes at least an image of the tissue sample positioned on a slide, the image including one or more demarcations each corresponding to a particular one of one or more regions-of-interest (ROIs) selected by a user, each of the selected one or more ROIs corresponding to a specific portion of the tissue sample within the tissue image;

display, in a second display, a visualization pane comprising a visualization of one or more biological expressions corresponding to the respective target biological components contained within one or more of the selected ROIs, wherein the one or more biological expressions are determined by analyzing cleaved, associated oligonucleotides from each of the selected ROIs; and

augment the first display by coding the one or more ROIs in the tissue image to show the spatial mapping of the biological expressions within the one or more ROIs.

2. The system of claim 1 , wherein coding the one or more ROIs in the tissue image comprises at least color-coding.

3. The system of claim 2 , wherein color-coding the one or more ROIs includes presenting a quantitative measurement of the one or more biological expressions.

4. The system of claim 1 , wherein the visualization comprises at least one of a graph, a plot, a diagram, and a map of the one or more biological expressions contained in the one or more ROIs.

5. The system of claim 1 , wherein the first display is augmented based upon user input specifying at least one selection of a biological expression contained in the visualization.

6. The system of claim 5 , wherein the spatial mapping of the at least one user selected biological expression is configured to provide spatial context thereof to at least one of the one or more of the ROIs.

7. The system of claim 1 , wherein augmenting the first display is configured to facilitate morphological profiling of tissue in at least one of the one or more ROIs.

8. The system of claim 7 , wherein morphological profiling comprises at least one of geometric profiling, segment profiling, contour profiling, gridded profiling, and cell profiling.

9. The system of claim 8 , wherein segment profiling comprises at least one of manual segment profiling and automatic segment profiling, the automatic segment profiling configured to automate and facilitate segment profiling of tissue in at least one of the one or more ROIs based on user input specifying at least one segment profiling parameter.

10. The system of claim 8 , wherein cell profiling comprises single cell profiling and rare cell profiling.

11. The system of claim 1 , wherein:

the one or more biological expressions are determined based upon exposing the tissue sample to a plurality of reagents,

the plurality of reagents include a plurality of imaging reagents configured to bind to biological boundaries of the tissue sample within at least the one or more ROIs, and

each of the plurality of profiling reagents being configured to bind to a specific biological expression of a specific target biological component contained within at least the one or more ROIs.

12. The system of claim 11 , wherein each profiling reagent comprises:

a nucleic acid probe including a target binding region in which the cleavable, associated oligonucleotide is removably linked; or

an oligonucleotide including a removably linked antibody.

13. The system of claim 1 ,

wherein the instructions are configured to cause the system to acquire the image of the tissue sample after the tissue sample is exposed to a plurality of reagents comprising the plurality of profiling reagents, wherein the selected ROIs are selected with respect to shape or size, and wherein the instructions are further configured to cause the system to:

collect the cleaved, associated oligonucleotides; and

analyze the collected, cleaved, associated oligonucleotides to determine the one or more biological expressions contained within one or more of an irradiated ROIs, and their corresponding location therein.

14. The system of claim 1 , wherein the instructions are further configured to cause the system to:

display, in a third display, a datasets pane which includes at least one user-selectable dataset, the at least one dataset associated with at least one of the one or more biological expressions contained in the one or more ROIs.

15. The system of claim 1 , wherein the scans pane further includes a plurality of icons each corresponding to a specific segment within at least one of the one or more ROIs or the overall tissue image.

16. The system of claim 1 , wherein coding the one or more ROIs includes presenting a quantitative measurement of the one or more biological expressions.

17. The system of claim 16 , wherein the quantitative measurement corresponds to at least one of a type and degree of respective biological expressions.

18. A non-transitory processor-readable medium storing code representing instructions, the instructions configured to be executed by a processor of a tissue sample biological expression mapping system, and the biological expression mapping system configured to spatially map one or more biological expressions of respective target biological components contained in a tissue sample to an image of the tissue sample, the instructions, when executed, configured to cause the system to:

display, in a first display, a scans pane which includes at least the image of the tissue sample positioned on a slide, the image including one or more demarcations each corresponding to a particular one of one or more regions-of-interest (ROIs) selected by a user, each of the selected one or more ROIs corresponding to a specific portion of the tissue sample within the tissue image;

display, in a second display, a visualization pane comprising a visualization of the one or more biological expressions corresponding to respective target biological components contained within one or more ROIs, wherein the one or more biological expressions are determined by analyzing cleaved, associated oligonucleotides from each of an irradiated ROIs; and

augment the first display by coding the one or more ROIs in the tissue image to show the spatial mapping of the biological expressions within the one or more ROIs.

19. A tissue sample analysis method, comprising:

displaying, in a first display, a scans pane which includes at least an image of the tissue sample positioned on a slide, the image including one or more demarcations each corresponding to a particular one of one or more regions-of-interest (ROIs) selected by a user, each of the selected one or more ROIs corresponding to a specific portion of the tissue sample within the tissue image;

displaying, in a second display, a visualization pane comprising a visualization of one or more biological expressions corresponding to respective target biological components contained within one or more of the ROIs, wherein the one or more biological expressions are determined by analyzing cleaved, associated oligonucleotides from each of the ROIs; and

augmenting the first display or the second display by coding the one or more ROIs in the tissue image to show the spatial mapping of the biological expressions within the one or more ROIs.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2024
From: NANOSTRING TECHNOLOGIES, INC.
To: BRUKER SPATIAL BIOLOGY, INC.
Reel/Frame 070944/0372 →
RELEASE OF SECURITY INTEREST Recorded May 16, 2024
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: NANOSTRING TECHNOLOGIES, INC.
Reel/Frame 067453/0565 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2024
From: NANOSTRING TECHNOLOGIES, INC.
To: BRUKER SPATIAL BIOLOGY, INC.
Reel/Frame 067932/0109 →
RELEASE OF SECURITY INTEREST Recorded May 16, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: NANOSTRING TECHNOLOGIES, INC.
Reel/Frame 067453/0577 →
SECURITY INTEREST Recorded Feb 8, 2024
From: NANOSTRING TECHNOLOGIES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 066528/0634 →
SECURITY INTEREST Recorded Nov 7, 2023
From: NANOSTRING TECHNOLOGIES, INC.
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 065490/0058 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2022
From: ASKOVICH, PETER; BALASUNDARAM, GAYATHRI; BEECHEM, JOSEPH M.; MCKEAN, MICHAEL; WILKINS, BISHOP
To: NANOSTRING TECHNOLOGIES, INC.
Reel/Frame 059960/0626 →
Continuity (2)
Provisional Application 62916990 · Oct 18, 2019
Related Publication 20240296549A1 · Sep 5, 2024
References Cited (85)
US 5650844A · Aoki et al. · 1997 [cited by applicant]
US 6788359B2 · Lee et al. · 2004 [cited by applicant]
US 6972892B2 · Desimone et al. · 2005 [cited by applicant]
US 7036946B1 · Mosier · 2006 [cited by applicant]
US 9075907B2 · Fujimoto · 2015 [cited by applicant]
US 9703171B2 · Zhou et al. · 2017 [cited by applicant]
US 11137953B2 · Ohmura · 2021 [cited by applicant]
US 11800990B2 · White et al. · 2023 [cited by applicant]
US 12002572B2 · Beechem et al. · 2024 [cited by applicant]
US 20030007598A1 · Wang · 2003 [cited by examiner]
US 20060161287A1 · Simonis · 2006 [cited by applicant]
US 20090086316A1 · Kawahito · 2009 [cited by applicant]
US 20130260382A1 · Ghosh et al. · 2013 [cited by applicant]
US 20150219979A1 · Zhou et al. · 2015 [cited by applicant]
US 20150378143A1 · Auguste · 2015 [cited by applicant]
US 20160209635A1 · Yan · 2016 [cited by applicant]
US 20160314583A1 · Couch · 2016 [cited by examiner]
US 20170016909A1 · Beechem et al. · 2017 [cited by applicant]
US 20170262984A1 · Barnes · 2017 [cited by examiner]
US 20170309021A1 · Barnes et al. · 2017 [cited by applicant]
US 20180330510A1 · Watanabe · 2018 [cited by applicant]
US 20190236780A1 · Barnes · 2019 [cited by examiner]
US 20200080060A1 · Matheu et al. · 2020 [cited by applicant]
US 20200097727A1 · Stumpe · 2020 [cited by examiner]
US 20220076809A1 · Beechem et al. · 2022 [cited by applicant]
US 20230081232A1 · Weisenfeld · 2023 [cited by examiner]
US 20230238078A1 · Gonzalez Lozano · 2023 [cited by examiner]
US 20240347176A1 · Beechem et al. · 2024 [cited by applicant]
CN 1357753A · 2002 [cited by applicant]
CN 201166604Y · 2008 [cited by applicant]
CN 101738618A · 2010 [cited by applicant]
CN 101915615A · 2010 [cited by applicant]
CN 201837458U · 2011 [cited by applicant]
CN 102564590A · 2012 [cited by applicant]
CN 103149180A · 2013 [cited by applicant]
CN 103743485A · 2014 [cited by applicant]
CN 103913419A · 2014 [cited by applicant]
CN 205403956U · 2016 [cited by applicant]
CN 106017680A · 2016 [cited by applicant]
CN 106352978A · 2017 [cited by applicant]
CN 107589078A · 2018 [cited by applicant]
CN 107850768A · 2018 [cited by applicant]
CN 108225282A · 2018 [cited by applicant]
CN 108332855A · 2018 [cited by applicant]
JP 2003241108A · 2003 [cited by applicant]
JP 2008009298A · 2008 [cited by applicant]
JP 2008501436A · 2008 [cited by applicant]
JP 2008206969A · 2008 [cited by applicant]
JP 2016526687A · 2016 [cited by applicant]
JP 2017092730A · 2017 [cited by applicant]
JP 2017191287A · 2017 [cited by applicant]
JP 2018503906A · 2018 [cited by applicant]
JP 2018031890A · 2018 [cited by applicant]
JP 2018529314A · 2018 [cited by applicant]
WO WO2005117711A2 · 2005 [cited by applicant]
WO WO2013024600A1 · 2013 [cited by applicant]
WO WO2016107896A1 · 2016 [cited by applicant]
WO WO2017015097A1 · 2017 [cited by applicant]
WO WO2017015099A1 · 2017 [cited by applicant]
WO WO2018218085A2 · 2018 [cited by applicant]
WO WO2018231204A1 · 2018 [cited by applicant]
WO WO2020132577A1 · 2020 [cited by applicant]
WO WO2021076928A1 · 2021 [cited by applicant]
Blank, et al., Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma, Nature medicine, Nov. 2018, pp. 1655-1661, vol. 24, No. 11. [cited by applicant]
Amaria, R. N., et al., “Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma”, Nature Medicine (2018); 24(11): 1649-1654. [cited by applicant]
[Author Unknown] “Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only”, Food and Drug Administration (Nov. 25, 2013) [online] https://www.fda.gov/downloads/MedicalDevic… [cited by applicant]
[Author Unknown] “GeoMx Digital Spatial Profiler Data Analysis User Manual”, NanoString Technologies, Inc. (Jun. 2019); 84 pages. [cited by applicant]
[Author Unknown] “GeoMx™ Digital Spatial Profiler”, NanoString Technologies, Inc. (Feb. 2019); 7 pages. [cited by applicant]
[Author Unknown] “nCounter® Analysis System User Manual”, MAN-C0035-07 96, NanoString Technologies, Inc. (Jul. 2018); 96 pages. [cited by applicant]
Buchanan, K., et al., “Unlocking Predictive Potential for Response to Immunotherapy Digital Spatial Profiling Technology”, NanoString Technologies®, Inc. (Mar. 2019); 8 pages. [cited by applicant]
Cesano, A., et al., “Abstract 1371: Spatially-resolved, multiplexed digital characterization of protein distribution and abundance in FFPE tissue sections”, AACR 107th Annual Meeting (Apr. 16-20, 2016); 5 pages; doi.org… [cited by applicant]
Chen, P. C., et al., “An Augmented Reality Microscope for Real-time Automated Detection of Cancer”, Google AI Healthcare, Google, Inc. (Apr. 16, 2018); 21 pages with Supplementary Data. [cited by applicant]
Chenn, A., “Wnt/B-catenin signaling in cerebral cortical development”, Organogenesis (2008); 4(2): 76-80. [cited by applicant]
Dubeau, L., et al., “Southern Blot Analysis of DNA Extracted from Formalin-fixed Pathology Specimens”, Cancer Research (1986); 46(6): 2964-2969. [cited by applicant]
Eggermont, A. M. M., et al., “Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy”, New England Journal of Medicine (2016); 375(19): 1845-1855. [cited by applicant]
Goyal, A., et al., “S100b as a Prognostic Biomarker in Outcome Prediction for Patients with Severe Traumatic Brain Injury”, Journal of Neurotrauma (2013); 30(11): 946-957. [cited by applicant]
Jeong, H., et al., “Brain Inflammation and Microglia: Facts and Misconceptions”, Experimental Neurobiology (2013); 22(2): 59-67. [cited by applicant]
Mallory, F. B., “The Results of the Application of Special Histological Methods to the Study of Tumors”, The Journal of Experimental Medicine (1908); 10(5): 575-593. [cited by applicant]
Misharin, A. V., et al., “Flow Cytometric Analysis of Macrophages and Dendritic Cell Subsets in the Mouse Lung”, American Journal of Respiratory Cell and Molecular Biology (2013); 49(4): 503-510. [cited by applicant]
Müller, A. M., et al., “Expression of CD34 in Pulmonary Endothelial Cells in vivo”, Pathobiology (2002); 70(1): 11-17. [cited by applicant]
Mudanyali, O., et al., “Integrated rapid-diagnostic-test reader platform on a cellphone”, Lab Chip (2012); 12: 2678-2686. [cited by applicant]
Walter, P. R., “Placental pathologic changes in malaria. A histologic and ultrastructural study”, The American Journal of Pathology (1982); 109(3): 330-342. [cited by applicant]
Weber, J., et al., “Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma”, New England Journal of Medicine (2017); 377(19): 1824-1835. [cited by applicant]
Wiolchok, J. D., et al., “Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma”, New England Journal of Medicine (2017); 377(14): 1345-1356. [cited by applicant]
Xu, X., et al., “S100A9 promotes human lung fibroblast cells activation through receptor for advanced glycation end-product-mediated extracellular-regulated kinase 1/2, mitogen-activated protein-kinase and nuclear facto… [cited by applicant]